Phase I trial of 90Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Between January 2001 and September 2005, 19 patients with progressive B-cell non-Hodgkin's lymphoma were treated with a cohort-specific dose of yttrium-90 ibritumomab tiuxetan (0.10-0.20 mCi/kg) to determine appropriate dosing in patients who had previously received high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients were required to have adequate end organ function and bone marrow status. Patients had been treated with a median of three prior therapies (range, 1-9). The median time from ASCT to radioimmunotherapy was 28 months. Hematologic toxicities were dose-limiting and included grade 3-4 thrombocytopenia (53%), neutropenia (32%), and anemia (21%). The majority of grade 3-4 events occurred at the 0.2mCi/kg dose level. Nine patients responded (complete response, complete response unconfirmed, or partial response) to the therapy. At a median follow-up of 37 months, the 1-year event-free and overall survival rates were 26% and 57%, respectively. A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT.

Original languageEnglish (US)
Pages (from-to)683-690
Number of pages8
JournalLeukemia and Lymphoma
Volume48
Issue number4
DOIs
StatePublished - Apr 1 2007

Fingerprint

Stem Cell Transplantation
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Drug Therapy
Radioimmunotherapy
Neutropenia
Disease-Free Survival
ibritumomab tiuxetan
Anemia
Survival Rate
Bone Marrow
Therapeutics

Keywords

  • Autologous stem cell transplantation
  • High-dose chemotherapy
  • Ibritumomab tiuxetan
  • Non-Hodgkin's lymphoma
  • Radio immunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{54858b1707b1437191b78ee08bc4e6c2,
title = "Phase I trial of 90Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation",
abstract = "Between January 2001 and September 2005, 19 patients with progressive B-cell non-Hodgkin's lymphoma were treated with a cohort-specific dose of yttrium-90 ibritumomab tiuxetan (0.10-0.20 mCi/kg) to determine appropriate dosing in patients who had previously received high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients were required to have adequate end organ function and bone marrow status. Patients had been treated with a median of three prior therapies (range, 1-9). The median time from ASCT to radioimmunotherapy was 28 months. Hematologic toxicities were dose-limiting and included grade 3-4 thrombocytopenia (53{\%}), neutropenia (32{\%}), and anemia (21{\%}). The majority of grade 3-4 events occurred at the 0.2mCi/kg dose level. Nine patients responded (complete response, complete response unconfirmed, or partial response) to the therapy. At a median follow-up of 37 months, the 1-year event-free and overall survival rates were 26{\%} and 57{\%}, respectively. A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT.",
keywords = "Autologous stem cell transplantation, High-dose chemotherapy, Ibritumomab tiuxetan, Non-Hodgkin's lymphoma, Radio immunotherapy",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Loberiza, {Fausto R.} and Bociek, {Robert G} and Daniel Matso and Armitage, {James Olen}",
year = "2007",
month = "4",
day = "1",
doi = "10.1080/10428190601158639",
language = "English (US)",
volume = "48",
pages = "683--690",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Phase I trial of 90Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Loberiza, Fausto R.

AU - Bociek, Robert G

AU - Matso, Daniel

AU - Armitage, James Olen

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Between January 2001 and September 2005, 19 patients with progressive B-cell non-Hodgkin's lymphoma were treated with a cohort-specific dose of yttrium-90 ibritumomab tiuxetan (0.10-0.20 mCi/kg) to determine appropriate dosing in patients who had previously received high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients were required to have adequate end organ function and bone marrow status. Patients had been treated with a median of three prior therapies (range, 1-9). The median time from ASCT to radioimmunotherapy was 28 months. Hematologic toxicities were dose-limiting and included grade 3-4 thrombocytopenia (53%), neutropenia (32%), and anemia (21%). The majority of grade 3-4 events occurred at the 0.2mCi/kg dose level. Nine patients responded (complete response, complete response unconfirmed, or partial response) to the therapy. At a median follow-up of 37 months, the 1-year event-free and overall survival rates were 26% and 57%, respectively. A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT.

AB - Between January 2001 and September 2005, 19 patients with progressive B-cell non-Hodgkin's lymphoma were treated with a cohort-specific dose of yttrium-90 ibritumomab tiuxetan (0.10-0.20 mCi/kg) to determine appropriate dosing in patients who had previously received high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients were required to have adequate end organ function and bone marrow status. Patients had been treated with a median of three prior therapies (range, 1-9). The median time from ASCT to radioimmunotherapy was 28 months. Hematologic toxicities were dose-limiting and included grade 3-4 thrombocytopenia (53%), neutropenia (32%), and anemia (21%). The majority of grade 3-4 events occurred at the 0.2mCi/kg dose level. Nine patients responded (complete response, complete response unconfirmed, or partial response) to the therapy. At a median follow-up of 37 months, the 1-year event-free and overall survival rates were 26% and 57%, respectively. A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT.

KW - Autologous stem cell transplantation

KW - High-dose chemotherapy

KW - Ibritumomab tiuxetan

KW - Non-Hodgkin's lymphoma

KW - Radio immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=34247189654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247189654&partnerID=8YFLogxK

U2 - 10.1080/10428190601158639

DO - 10.1080/10428190601158639

M3 - Article

VL - 48

SP - 683

EP - 690

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -